Previous 10 | Next 10 |
Company expects to recruit hundreds of new hires in the area to support clinical research, development, regulatory, pharmacovigilance, and manufacturing BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innova...
It was an excruciating week of a severe emotional storm with the share prices undergoing a rollercoaster ride. A deluge of news, speculations, and commentaries overwhelmed the mind. The massive and synchronized sell-off of Chinese equities was akin to a Golden Slam for the critics. It...
BeiGene (NASDAQ:BGNE) announces positive topline results from an interim analysis of Phase 3 SEQUOIA trial comparing BRUKINSA (zanubrutinib) to bendamustine and rituximab (B+R) in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SL...
Trial met the primary endpoint at interim analysis, with BRUKINSA significantly prolonging progression-free survival compared to chemoimmunotherapy and safety and tolerability consistent with its known profile SEQUOIA is the second positive global Phase 3 trial of BRUKINSA in ...
Shares of BeiGene (NASDAQ: BGNE) were soaring 15.6% higher as of 3:38 p.m. EDT on Wednesday. The big jump came after the Chinese drugmaker filed a document to the U.S. Securities and Exchange Commission (SEC) related to the proposed public offering of its stock and listing on the Sc...
BeiGene's (BGNE) BRUKINSA (zanubrutinib) has been approved by Health Canada for the treatment of mantle cell lymphoma ((MCL)) in adult patients who have received at least one prior therapy.This is the second approval for BRUKINSA in Canada, following its initial approval in March 2021 fo...
Second approval for BTK Inhibitor BRUKINSA in Canada BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today ann...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA And Healthcare Dashboard For July
Insider buying declined last week. Olivier Goudet to buy shares of Krispy Kreme. Insiders continue to buy shares in new IPOs. For further details see: Insider Weekends: Insider Buying In New IPOs
BeiGene (BGNE) announces that the China National Medical Products Administration has conditionally approved Kyprolis (carfilzomib) for injection in combination with dexamethasone for the treatment of adults with relapsed or refractory (R/R) multiple myeloma who have received at least two prio...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...